Steven Cohen's TEVA Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.13 M shares of Teva Pharmaceutical Industries Limited (TEVA) worth $34.05 M, representing 0.04% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 5.42 M shares. Largest reduction occurred in Q3 2022, reducing 6.65 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.13 M | New Buy | 1.13 M | $30.12 |
| Q4 2024 | -517,712 | Sold Out | 0 | $0.00 |
| Q3 2024 | -801,505 | Reduce 60.76% | 517,712 | $18.02 |
| Q2 2024 | +363,217 | Add 37.99% | 1.32 M | $16.25 |
| Q1 2024 | -558,006 | Reduce 36.86% | 956,000 | $14.11 |
| Q4 2023 | -117,191 | Reduce 7.18% | 1.51 M | $10.44 |
| Q3 2023 | +689,739 | Add 73.26% | 1.63 M | $10.20 |
| Q2 2023 | +941,399 | Add 1595591.50% | 941,458 | $7.53 |
| Q1 2023 | +59 | New Buy | 59 | $8.85 |
| Q3 2022 | -6.65 M | Sold Out | 0 | $0.00 |
| Q2 2022 | +5.42 M | Add 441.02% | 6.65 M | $7.52 |
| Q1 2022 | +1.23 M | New Buy | 1.23 M | $9.39 |
| Q2 2021 | -1.57 M | Sold Out | 0 | $0.00 |
| Q1 2021 | +1.57 M | New Buy | 1.57 M | $11.54 |
| Q4 2020 | -180,714 | Sold Out | 0 | $0.00 |
| Q3 2020 | +180,714 | New Buy | 180,714 | $9.01 |
| Q4 2019 | -27,409 | Sold Out | 0 | $0.00 |
| Q3 2019 | +14,519 | Add 112.64% | 27,409 | $6.90 |
| Q2 2019 | +9,698 | Add 303.82% | 12,890 | $9.23 |
| Q1 2019 | +3,192 | New Buy | 3,192 | $15.66 |
| Q4 2018 | -414,100 | Sold Out | 0 | $0.00 |
| Q3 2018 | -3.32 M | Reduce 88.90% | 414,100 | $21.54 |
| Q2 2018 | +3.73 M | New Buy | 3.73 M | $24.32 |
| Q1 2018 | -327,650 | Sold Out | 0 | $0.00 |
| Q4 2017 | +202,650 | Add 162.12% | 327,650 | $18.95 |
| Q3 2017 | +125,000 | New Buy | 125,000 | $17.60 |
| Q1 2016 | -28,300 | Sold Out | 0 | $0.00 |
| Q4 2015 | -345,500 | Reduce 92.43% | 28,300 | $65.65 |
| Q3 2015 | +194,300 | Add 108.25% | 373,800 | $56.46 |
| Q2 2015 | +88,500 | Add 97.25% | 179,500 | $59.10 |
| Q1 2015 | -147,000 | Reduce 61.76% | 91,000 | $62.30 |
| Q4 2014 | +178,800 | Add 302.03% | 238,000 | $57.51 |
| Q3 2014 | -961,500 | Reduce 94.20% | 59,200 | $53.75 |
| Q2 2014 | +1.02 M | Add 0.00% | 1.02 M | $52.42 |
Steven Cohen's Teva Pharmaceutical Industries Limited Investment FAQs
Steven Cohen first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q2 2014, acquiring 1,020,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Teva Pharmaceutical Industries Limited (TEVA) for 34 quarters since Q2 2014.
Steven Cohen's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q2 2022, adding 6,653,979 shares worth $50.04 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,130,507 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $34.05 M.
As of the Q1 2026 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 0.04% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 6,653,979 shares, as reported at the end of Q2 2022.